DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1046524
Title:
A Phase 1 Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer
Corporate Author:
University Of California, Davis Davis United States
Report Date:
2017-10-01
Abstract:
This clinical trial is the first to evaluate the synergy between radiation, a well-known immune modulator, with the novel immune checkpoint inhibitor MPDL3280A atezolizumab in early stage inoperable non-small cell lung cancer. The trial is comprised of a traditional 3 3 phase I design followed by a dose expansion. We have enrolled 3 patients into dose level 1.Two patients have completed the entire treatment plan and 1 patient is in the 9-week dose limiting time period. The regimen has been well tolerated with no dose limiting toxicities observed in the first two patients. One patient had a partial response and the other patient has stable disease. Interestingly patient 1 had tumor shrinkage after two cycles of low dose MPDL3280A without the radiation. The trial continues as planned.
Descriptive Note:
Technical Report,30 Sep 2016,29 Sep 2017
Pages:
0010
Distribution Statement:
Approved For Public Release;
File Size:
0.16MB
